KINREL

Every medium-sized pharma-biotech company has two crucial departments in its strategic development: the medical department, specialized in regulatory affairs, and the industrial property department, which ensures the correct protection of the results of its research.

The formulation of an appropriate clinical development strategy and patentability strategy must be taken into account from the beginning of a biotechnology company, so it is important to have multidisciplinary knowledge in these fields from the moment the company is established, or even earlier, when the project is still managed by the University's OTRI.

Specific consultations with specialized companies such as regulatory consultancies or patent agencies are decisive in decision-making, but even more important is to follow up in house, by a person who knows the global strategy of the company through direct collaboration with the researchers and founders of the company.

We want to be part of your team, and help you create a strategic plan from the beginning.